Reuters logo
BRIEF-FDA accepts Spark Therapeutics's application to review Luxturna
July 17, 2017 / 11:45 AM / 2 months ago

BRIEF-FDA accepts Spark Therapeutics's application to review Luxturna

July 17 (Reuters) - Spark Therapeutics Inc-

* Spark Therapeutics’ biologics license application for investigational voretigene neparvovec accepted for filing by FDA

* Says for review of Luxturna, FDA has assigned a PDUFA date of Jan. 12, 2018

* Says Luxturna (voretigene neparvovec) unveiled as proposed trade name Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below